Cristiane D Bergerot, Former Postdoc Fellow and Research Consultant at City of Hope, shared posts on X highlighting her ASCO26 abstract picks. The selected studies cover key clinical updates and emerging research expected to draw attention during this year’s:
1. “Heading to ASCO26 next week? Stop by Koral Shaհ poster session to discuss new data on biomarker-defined outcomes in metastatic clear cell RCC and how genomics may shape first-line treatment decisions. Looking forward to connecting!”
Title: Biomarker-defined outcomes in metastatic clear cell renal cell carcinoma (mccRCC) receiving first-line (1L) immune checkpoint inhibitor-based therapy.
Authors: Koral U. Shah, Jennifer Rider, Ryan Pindale, Miguel Zugman, Salvador Jaime-Casas, Vitor Abreu De Goes, Ali Moradi, Nicholas Salgia, Peter D. Zang, Daniela V. Castro, Benjamin Mercier, George Zhang, Yujun Li, Nazli Dizman, Joann Hsu, Wesley Yip, Abhishek Tripathi, Charles B. Nguyen, Alex Chehrazi-Raffle, Sumanta K. Pal
Read the Full Abstract.
2. “ASCO26 starts next week! Can selected patients with aUC safely take a break from treatment? Join Salvador Jaime-Casas at poster session to discuss RWD on treatment-free survival w EV-based therapy and the potential role of treatment de-escalation strategies.”
Title: Treatment-free survival (TFS) in patients with advanced urothelial carcinoma (aUC) treated with enfortumab vedotin (EV)–based therapy.
Authors: Salvador Jaime-Casas, Koral U. Shah, George Zhang, Jadon C. Fann, Vitor Abreu De Goes, Miguel Zugman, Ali Moradi, Nicholas Salgia, Daniela V. Castro, Benjamin Mercier, Nazli Dizman, Joann Hsu, Wesley Yip, Xiaochen Li, Alexander Chehrazi-Raffle, Sumanta K. Pal, Abhishek Tripathi
Read the Full Abstract.
3. “Can targeted radiopharmaceutical therapy change the landscape of advanced clear cell RCC? ASCO26 Phase 3 LUTEON study evaluating 177Lu-girentuximab in relapsed or recurrent disease.”
Title: Phase 3 study to assess the safety and efficacy of 177Lu-girentuximab
in advanced, relapsed, or recurrent ccRCC (LUTEON)
Authors: David Cade, Sumanta K. Pal, Andrew M. Scott, Thea Faivre
Read the Full Abstract.
4. “Can combining HIF-2α inhibition with targeted therapy help reshape treatment for advanced clear cell RCC? ASCO26 PEAK-1, an ongoing Phase 3 trial evaluating casdatifan + cabozantinib in patients progressing after PD-1/PD-L1 therapy.”
Title: PEAK-1: A randomized, double-blind, active-control, multicenter phase 3 trial of casdatifan and cabozantinib versus placebo and cabozantinib in patients with advanced clear cell renal cell carcinoma.
Authors: Toni K. Choueiri, Sumanta K. Pal, Rana R. McKay, Cristina Suárez, John Haanen, Deepti Warad, Christopher Negro, Melissa J. Eisen, Paul G. Foster, Thomas Powles
Read the Full Abstract.
5. “Can we better protect hearing without compromising treatment in metastatic germ cell tumors? ASCO26 Phase 1 study evaluating sodium thiosulfate alongside cisplatin-based chemotherapy.”
Title: Randomized phase 1 trial of cisplatin-based chemotherapy with or without sodium thiosulfate for men with metastatic germ cell tumor (GCT).
Authors: Koral U. Shah, Xiaochen Li, Tanya B. Dorff, Sumanta K. Pal, Abhishek Tripathi, Charles B. Nguyen, Pierre S. Sayad, Alex Chehrazi-Raffle
Read the Full Abstract.
6. “How close to the EOL are patients still receiving anti-cancer treatment?
Real-world treatment patterns across 6 common cancers and the implications for patient-centered care, palliative care integration, and quality of care delivery.”
Title: End-of-life anti-cancer treatment (Rx) patterns in patients (pts) with the six most common cancers in the USA.
Authors: Umang Swami, Yeonjung Jo, Varun Nandakumar, Zeynep Irem Ozay, Georges Gebrael, Edwin Lin, Ethan Murdock, Gabriel Hooper, Richard T. Hardy, Tejita Agarwal, Rachel Revillo, Krishnam Goel, Ayana Srivastava, Benjamin L. Maughan, Vinay Mathew Thomas, Haoran Li, Sumanta K. Pal, Rana R. McKay, Neeraj Agarwal
Read the Full Abstract.
7. “Excited for ASCO26 oral presentations! New analyses from KEYNOTE-564 will explore how ctDNA status and ctDNA clearance relate to outcomes in RCC treated w adjuvant pembrolizumab.”
Title: ctDNA analysis in participants with renal cell carcinoma treated with adjuvant pembrolizumab or placebo in the KEYNOTE-564 trial.
Authors: Toni K. Choueiri, Piotr Tomczak, Naomi B. Haas, David F. McDermott, Balaji Venugopal, Se Hoon Park, Thomas Ferguson, Stefan N. Symeonides, Wayne Yen Hwa Chang, Jae Lyun Lee, Naveed Sarwar, Piotr Sawrycki, Chen-Hua Chuang, Yiwei Zhang, Razvan Cristescu, Cai Chen, Carol E. Pena, Rodolfo F. Perini, Joseph E. Burgents, Thomas Powles
Read the Full Abstract.
8. “Final TiNivo-2 analysis exploring long-term outcomes with tivozanib in metastatic RCC.
New data continue to inform treatment strategies and sequencing decisions after prior immunotherapy.”
Title: Final analysis of the TiNivo-2 phase 3 trial: Long-term outcome of
tivozanib (Tivo) in patients with metastatic renal cell carcinoma
(mRCC).
Authors: Robert J. Motzer, Bradley A. McGregor, Laurence Albiges, Javier Molina Cerrillo, Philippe Barthélémy, Maria T. Bourlon, Benjamin Garmezy, Sheik Emambux, Arnab Basu, Raffaele Ratta, Pedro C. Barata, Jeffrey T. Yorio, Helen Moon, Alex Chehrazi-Raffle, Roberto Iacovelli, Ralph J. Hauke, Rana R. McKay, Kathryn E. Beckermann, Moshe C. Ornstein, Toni K. Choueiri
Read the Full Abstract.
9. “Do patients with bone metastases derive sustained benefit from first-line immunotherapy-based combinations in advanced RCC?
Updated subgroup analyses from CheckMate-9ER and long-term outcomes with cabozantinib + nivolumab․”
Title: Cabozantinib plus nivolumab (C+N) versus sunitinib (S) in patients with advanced renal cell carcinoma (aRCC) and bone metastasis: Updated subgroup analysis of the phase 3 CheckMate-9ER trial.
Authors: Andrea B. Apolo, Bernard Escudier, Thomas Powles, Maria T. Bourlon, Cristina Suárez, Camillo Porta, Saby George, Toni K. Choueiri, Robert J. Motzer, Joshua Zhang, Denise S. Williamson, Lana Andrianova, Jose R. Perez, Tasha D. Hall, Amishi Y. Shah
Read the Full Abstract.
10. “Excited for ASCO26 updates in urothelial cancer! New long-term EV-302 findings continue to evaluate outcomes w EV + pembrolizumab, w intriguing analyses on patients whose responses evolved from partial to complete response over time․”
Title: Enfortumab vedotin plus pembrolizumab (EV+P) vs chemotherapy for previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC): 3.5-year follow-up and response analyses from the phase 3 EV-302 study.
Authors: Thomas Powles, Michiel S. Van Der Heijden, Jens Bedke, Begoña P. Valderrama, Eiji Kikuchi, Matthew D. Galsky, Yohann Loriot, Gopa Iyer, Evan Y. Yu, Jeannie Hoffman-Censits, Nataliya Mar, Christof Vulsteke, Srikala S. Sridhar, Jose Pablo Maroto-Rey, Se Hoon Park, Blanca Homet Moreno, Jasmine Lichfield, Xuesong Yu, Heidi Wirtz, Shilpa Gupta
Read the Full Abstract.
11. “Can low-grade toxicities have a greater impact on patients than we realize?
Let’s explore how patient-reported experiences and long-term treatment effects may shape decision regret following adjuvant pembrolizumab in RCC․”
Title: Decision regret and toxicity perception following adjuvant pembrolizumab in renal cell carcinoma.
Authors: Elizabeth Nally, Veda Kudva, Gina Sherpa, Yifan Wang, Federica Sordelli, Giuseppe Basile, Sara Coca Membribes, Catherine Graham, Francesca Jackson-Spence, Bernadett E. Szabados, Naveed Sarwar, Axel Bex, Antonio Rullan, Thomas Powles
Read the Full Abstract.
12. “Improving outcomes is critical, but so is preserving quality of life.
Patient-reported outcomes from IMvigor011 and what ctDNA-guided adjuvant treatment may mean for patients with muscle-invasive bladder cancer․”
Title: Patient-reported outcomes from IMvigor011: A phase 3 study of circulating tumor (ct)DNA–guided adjuvant atezolizumab vs placebo in muscle-invasive bladder cancer (MIBC).
Authors: Joaquim Bellmunt, Shilpa Gupta, Miguel A. Climent Duran, Fatih Köse, Karine Martins da Trindade, Naiara Sagastibelza Marinelarena, Rosa Tambaro, Robert A. Huddart, Pablo Gajate, Alison J. Birtle, Hongqian Guo, Tomoya Fukawa, Atsushi Komaru, Yukio Kageyama, Wataru Obara, Bo Ci, Elizabeth Steinberg, Janelle Soong, Siobhán Connor-Ahmad, Thomas Powles
Read the Full Abstract.
13. “One to watch at ASCO26: TALAPRO-3, a Late-Breaking Oral Abstract evaluating talazoparib + enzalutamide in HRR-altered metastatic castration-sensitive prostate canceռ․”
Title: TALAPRO-3: Talazoparib (TALA) + enzalutamide (ENZA) compared with placebo (PBO) + ENZA for the treatment of patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) harboring homologous recombination repair (HRR) gene alterations.
Authors: Neeraj Agarwal, Nobuaki Matsubara, Arun Azad, Fred Saad, Joaquin Mateo, Shusuan Jiang, Dingwei Ye, Eric Voog, Neal D. Shore, Timucin Cil, Christof Vulsteke, Hsiao-Jen Chung, Stefanie Zschaebitz, Douglas Laird, Xiaoxi Zhang, Prachi Nandoskar, Sarah Fenech Chetcuti, Fong Wang, Karim O. Fizazi
Read the Full Abstract.
14. “One to watch at ASCO26: preliminary Phase 3 ProstACT Global results evaluating 177Lu-rosopatamab tetraxetan plus standard of care in metastatic castration-resistant prostate cancer․”
Title: Safety and dosimetry of 177Lu-rosopatamab tetraxetan plus SoC in patients with metastatic castration-resistant prostate cancer: Preliminary results from part 1 of phase 3 ProstACT Global study.
Authors: Pedro C. Barata, Gary Tincknell, David M. Gill, Simon Y. Fu, Aviral Singh, Alton O. Sartor, David Cade, Neeraj Agarwal
Read the Full Abstract.
15. “Could baseline cognitive performance help identify treatment trajectories in prostate cancer? New findings at ASCO26 evaluating cognition and treatment response in patients receiving apalutamide + ADT․”
Title: Cognition of apalutamide + ADT treatment responders versus non-responders.
Authors: Arun Azad, Marco A. Badillo, Alicia K. Morgans, Dana Rathkopf, Karie Runcie, Geoffrey Gotto, Axel S. Merseburger, Alex Dos Santos, Jingwei Li, Sukie Shopeju, Meenakshi Chatterjee, Rana Zia Ur Rehman, Daniel P. Sanchez, Bhavini Patel, Amitabha Bhaumik, Vasanth Thirugnanam, Yanran Huo, Ashita S. Batavia, Mark A. Wildgust, Neeraj Agarwal
Read the Full Abstract.
16. “ASCO26 starts next week! Polypharmacy is a reality for many patients with advanced prostate cancer. Post-hoc analyses from TITAN and SPARTAN evaluating concomitant medication use w apalutamide and implications for routine clinical practice․”
Title: Evaluation of concomitant medications in advanced prostate cancer patients receiving apalutamide: TITAN and SPARTAN post-hoc analysis.
Authors: Neeraj Agarwal, Geoffrey Gotto, Álvaro Juárez Soto, Nishant Sangole, Amitabha Bhaumik, Silva Libohova, Alex Yu, Kim N. Chi
Read the Full Abstract.
17. “Can targeted androgen receptor degradation help overcome resistance in metastatic prostate cancer?
ANDROMEDA will evaluate AZD9750 and new approaches to AR-directed therapy․”
Title: Phase I/II study to evaluate AZD9750, a novel androgen receptor proteolysis-targeting chimera, alone and in combination with other anticancer agents in patients with metastatic prostate cancer (ANDROMEDA).
Authors: Neeraj Agarwal, Steven M. Yip, Rahul R. Aggarwal, Xin Gao, Simon Pacey, Kim N. Chi, Joaquin Mateo, Neal D. Shore, Wassim Abida, Boaz E. Aronson, Neel Shah, Massimo Squatrito, Huifang Chen, Yu Jiang, Jane Peters, Silvija Kraljevic, Michael Niedbala, Arun Azad
Read the Full Abstract.
18. “One to watch at ASCO26: first-in-human data evaluating ABBV-969, a novel dual-targeting PSMA/STEAP1 antibody-drug conjugate in metastatic castration-resistant prostate cancer. Excited to see emerging approaches in advanced disease․”
Title: A phase 1, first-in-human (FIH) study evaluating the safety, pharmacokinetics, and efficacy of ABBV-969 in patients with metastatic castration-resistant prostate cancer (mCRPC).
Authors: Tanya B. Dorff, Avivit Peer, Manish R. Sharma, Anthony M. Joshua, John D. Powderly II, Yutaka Shimazu, Rahul R. Aggarwal, Benedito A. Carneiro, Russell Z. Szmulewitz, Linu Abraham, Sumiko Okubo, Claudina Stevenson, Samaneh Alaei, Song Wang, Muhammad Jalaluddin, Oluwadamilola Ogunyankin, Sarah Mudd, David I. Quinn, Fred Saad, Anthony W. Tolcher
Read the Full Abstract.
19. “Can conversational AI help bring geriatric assessment into everyday oncology care?
GRACE and its potential role in supporting older adults with cancer․”
Title: GRACE: A conversational AI platform for geriatric oncology risk and capability evaluation.
Authors: Arash Naeim, Justin Cheng, Brennan Spiegel, Alexandra Bakshian, Ella Tetrault, Muskaan Mehra, Dian Amini, Zoe Krut, Helen Shang, Mina S. Sedrak, Alex Bui, Taylor Johnson, Raymond Wang, Omer Liran
Read the Full Abstract.
20. “Are we identifying and addressing cancer cachexia early enough in older adults? Looking forward to ASCO26 discussions on the relationship between cachexia and symptomatic toxicity in patients receiving cancer treatment․”
Title: Cancer cachexia and symptomatic toxicity among 706 older adults with advanced cancer receiving treatment: A URCC NCORP nationwide study.
Authors: Lindsey J. Mattick, Supriya G. Mohile, Karen M. Mustian, Chin-Shang Li, Marie A. Flannery, Mostafa R. Mohamed, Rachael Tylock, Po-Ju Lin, Yuri Choi, Khalil Katato, Jeffrey L. Berenberg, Nadia N. Ramdin, Richard F. Dunne
Read the Full Abstract.
21. “Older adults w AML discuss multiple priorities during treatment decisions, but many values are not explored in depth The URGOAL communication intervention showed greater patient engagement and improved value alignment․”
Title: Pilot RCT of a patient-centered communication intervention to promote values-based treatment decision-making in older adults with AML.
Authors: Rachel Rodenbach, Atena Rahman, Yingzhu Chen, Emily Oh, Soroush Mortaz, Jason H. Mendler, Jane Liesveld, Eric Huselton, Bassil Botros, Craig Maguire, Ronald M. Epstein, Sally Norton, Joanne Terhune, Jim Terhune, Supriya G. Mohile, Heidi D. Klepin, Daniel R. Richardson, Kah Poh Loh
Read the Full Abstract.
22. “Survivorship remains underrepresented ASCO despite a growing survivor population Across 8,928 abstracts from 2022–2024, only 6.4% were survivorship-focused, w limited growth over time and frequent gaps in defining populations and survivorship contexts․”
Title: Survivorship-focused content at the American Society of Clinical Oncology (ASCO) 2022-2024 annual meetings.
Authors: Lauren Rynar, Sandra Naaman, Benjamin Bates, Mercedes Castiel, Douglas E. Peterson, Julien Vos, Imdat Eroglu, Joseph W. McCollom, David H. Noyd, Christine A. Garcia, Nicole Agaronnik, Melinda L. Hsu, Kelley C. Wood, Padmaja V. Mallidi, Rejin Kebudi, Niharika Dixit, Larissa Nekhlyudov
Read the Full Abstract.
23. “Integrating pallcare within community oncology practice was associated w higher rates of hospice referral and advance care planning documentation, without increasing hospital or ICU utilization․”
Title: A retrospective cohort studying integrative palliative care in a community oncology practice: Impact and outcomes.
Authors: Summiya Nasim, Molly Jain, Madeline Ku, Peyton Clouse, Joseph W. McCollom
Read the Full Abstract.
24. “How patients cope during early-phase cancer clinical trials may matter beyond emotional wellbeing Longitudinal changes in coping strategies were associated w QOL, symptoms, time on trial, and overall survival․”
Title: Longitudinal changes in coping among early phase cancer clinical trial (EPCT) participants.
Authors: Anh B. Lam, Andrea Pelletier, Sienna M. Durbin, Rachel Jimenez, Cynthia Moore, Kaitlyn Lynch, Laura A. Petrillo, Leah L. Thompson, Casandra McIntyre, Dejan Juric, Ryan D. Nipp, Debra Lundquist
Read the Full Abstract.
25. “Among patiens in early-phase cancer clinical trials, improvements in QOL over time were associated w longer time on trial and lower healthcare utilization․ Tracking and addressing PROs may optimize patient experience and clinical outcomes․”
Title: Longitudinal changes in patient-reported quality of life (QOL) and hope among early phase cancer clinical trial (EPCT) participants.
Authors: Debra Lundquist, Andrea Pelletier, Sienna M. Durbin, Rachel Jimenez, Anh B. Lam, Cynthia Moore, Allison White, Leah L. Thompson, Laura A. Petrillo, Kaitlyn Lynch, Casandra McIntyre, Dejan Juric, Ryan D. Nipp
Read the Full Abstract.
Other articles featuring Cristiane D Bergerot on OncoDaily.
